6 completed, 3 terminated, 2 recruiting, 1 withdrawn. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Terminated 3, Recruiting 2, Withdrawn 1 |
Follow KD025: new trials by email Literature Review of KD025 trials Research Report on KD025
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | Kadmon, a Sanofi Company | 2025-06-16 | 2026-02-12 | |
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Belumosudil, Fluticasone, Azithromycin - Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2024-05-31 | 2026-06-10 |
| Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease Belumosudil, Biospecimen Collection, Electronic Health Record Review - Chronic Graft Versus Host Disease | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 82 | 2023-12-06 | 2026-09-17 |
| Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD) BN101 - GVHD, Chronic | Phase 2 | Completed | BioNova Pharmaceuticals (Shanghai) LTD. | 30 | 2021-04-27 | 2024-01-17 |
| Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 10 | 2021-03-03 | 2023-06-05 |
| KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil (KD025), Placebo - System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 36 | 2019-06-26 | 2023-08-30 |
| Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Belumosudil (KD025) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | Kadmon, a Sanofi Company | 159 | 2018-10-11 | 2024-12-12 |
| A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease Belumosudil (KD025) - Graft vs Host Disease | Phase 2 | Completed | Kadmon, a Sanofi Company | 54 | 2016-09-15 | 2023-06-28 |
| A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis Belumosudil, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | Kadmon Corporation, LLC | 110 | 2016-09-14 | 2022-03-16 |
| A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis Belumosudil, BSC - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Kadmon Corporation, LLC | 76 | 2016-05-26 | 2022-09-08 |
| Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy KD025 - Psoriasis Vulgaris | Phase 2 | Completed | Kadmon Corporation, LLC | 38 | 2014-12-01 | 2022-05-26 |
| A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Belumosudil - Psoriasis Vulgaris | Phase 2 | Completed | Kadmon Corporation, LLC | 8 | 2014-04-01 | 2022-03-23 |
Bronchiolitis Obliterans Syndrome (5) · Lung Diseases (2) · Scleroderma, Diffuse (2) · Skin Diseases (2) · Bronchiolitis Obliterans (1) · Fibrosis (1) · Graft vs Host Disease (1) · Idiopathic Interstitial Pneumonias (1) · Idiopathic Pulmonary Fibrosis (1) · Immune System Diseases (1) · Plaque, Amyloid (1) · Pulmonary Fibrosis (1) · Scleroderma, Systemic (1)
Kadmon, a Sanofi Company (5) · Kadmon Corporation, LLC (4) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Dana-Farber Cancer Institute (1) · Fred Hutchinson Cancer Center (1)
United States (10) · China (1)
Corey Cutler, MD, MPH (1) · Depei Wu, Prof (1) · Stephanie Lee, MD, MPH (1)
PMID 35781099, PMID 33877856, PMID 34265047, PMID 38532458, PMID 40088930, PMID 40311075